Week of June 25, 2012: Bend Research, Catalent Enter into Oral Controlled-Release Technologies Pact; Quintiles Expands in China; and More - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Week of June 25, 2012: Bend Research, Catalent Enter into Oral Controlled-Release Technologies Pact; Quintiles Expands in China; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Adventrx and Patheon have entered into a manufacturing agreement under which Patheon will formulate, fill, and finish ANX-188 drug product for use in clinical trials, including the Phase III study of ANX-188 that AdventRX plans to initiate this year. Read More

Bend Research and Catalent Pharma Solutions have agreed to provide services for pharmaceutical companies seeking to develop and manufacture specialized multiparticulate oral controlled-release products. Under the agreement, the companies will provide an integrated approach designed to bring complex controlled-release products to market faster and more efficiently with optimal therapeutic and release profiles. Read More

Merck Serono and Compugen, a therapeutic product-discovery company, has established Neviah Genomics, a start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will use certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Read More

The CRO Quintiles has agreed to establish a regional headquarters in Shanghai, to significantly expand laboratory-testing capabilities in China. Under a joint venture agreement, Quintiles will engage Shanghai Clinical Research Center to provide laboratory-testing services to local customers. To provide the infrastructure essential for its growth strategy in China, Quintiles is investing $14 million to establish a new 4000-m2 (43,000 ft2) headquarters in Shanghai to serve China and nearby Asian countries. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here